IP Library Granted Patent US 7,670,823
Granted Patent B1
US 7,670,823 · App. 09/517,466 · Granted Mar 2, 2010

Compositions for use in recombinational cloning of nucleic acids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,670,823
App. No.
09/517,466
Granted
Mar 2, 2010
Kind
B1
Abstract

The present invention relates generally to compositions and methods for use in recombinational cloning of nucleic acid molecules. In particular, the invention relates to nucleic acid molecules encoding one or more recombination sites or portions thereof, to nucleic acid molecules comprising one or more of these recombination site nucleotide sequences and optionally comprising one or more additional physical or functional nucleotide sequences. The invention also relates to vectors comprising the nucleic acid molecules of the invention, to host cells comprising the vectors or nucleic acid molecules of the invention, to methods of producing polypeptides using the nucleic acid molecules of the invention, and to polypeptides encoded by these nucleic acid molecules or produced by the methods of the invention. The invention also relates to antibodies that bind to one or more polypeptides of the invention or epitopes thereof. The invention also relates to the use of these compositions in methods for recombinational cloning of nucleic acids, in vitro and in vivo, to provide chimeric DNA molecules that have particular characteristics and/or DNA segments.

Claims (11)

1. An isolated nucleic acid molecule comprising a lambda att recombination site wherein a sequence of the seven base pair overlap region within the fifteen base pair core region is ATTATAC.

2. The isolated nucleic acid molecule of claim 1 , which comprises two or more lambda att recombination sites.

3. The isolated nucleic acid molecule of claim 1 , wherein the lambda att-recombination site is located between a transcriptional regulatory sequence and an open reading frame, wherein the transcriptional regulatory sequence and open reading frame are operably linked.

4. The isolated nucleic acid molecule of claim 3 , wherein the transcriptional regulatory sequence is a promoter.

5. The isolated nucleic acid molecule of claim 1 , which is a vector.

6. The isolated nucleic acid molecule of claim 5 , wherein the vector is a plasmid.

7. The isolated nucleic acid molecule of claim 1 , which further comprises at least one origin of replication.

8. The isolated nucleic acid molecule of claim 7 , which comprises at least two origins of replication.

9. The isolated nucleic acid molecule of claim 7 , which comprises at least one origin of replication that allows for replication of the nucleic acid molecule in a prokaryotic cell.

10. The isolated nucleic acid molecule of claim 9 , wherein the prokaryotic cell is an Escherichia coli cell.

11. An isolated host cell comprising one or more isolated nucleic acid molecules of claim 1 .

Assignments (4)
MERGER Recorded Jan 7, 2014
From: LIFE TECHNOLOGIES, INC.
To: INVITROGEN CORPORATION
Reel/Frame 031906/0503 →
MERGER Recorded Jan 7, 2014
From: LT NAME CORPORATION
To: INVITROGEN CORPORATION; LIFE TECHNOLOGIES CORPORATION
Reel/Frame 031906/0718 →
LIEN RELEASE Recorded Apr 9, 2013
From: BANK OF AMERICA, N.A.
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 030182/0461 →
SECURITY AGREEMENT Recorded Dec 5, 2008
From: LIFE TECHNOLOGIES CORPORATION
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 021975/0467 →